Instrument Inactif

Communiqués Compugen Ltd. Deutsche Boerse AG

Actions

CW9

IL0010852080

Temps réel estimé Tradegate Autres places de cotation 16:20:28 17/07/2024			Varia. 5j.	Varia. 1 janv.
1,701 ^EUR	-66,32%		-9,82%	0,00%

27/06	Transcript : Compugen Ltd. - Special Call
30/05	Compugen Ltd. recevra un paiement d'étape d'Astrazeneca déclenché par le dosage du premier patient dans le deuxième essai de phase 3 évaluant le rilvegostomig	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Compugen to Present at Upcoming Antibody Industrial Symposium	17/06	PR
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	30/05	PR
Compugen : Reports First Quarter 2024 Results	20/05	PU
Compugen: Q1 Earnings Snapshot	20/05	AQ
Compugen Reports First Quarter 2024 Results	20/05	PR
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	16/05	PU
Compugen Appoints David Silberman as Chief Financial Officer	15/05	PR
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	06/05	PR
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	26/04	AQ
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	25/04	PU
Compugen to Participate in Two Upcoming Investor Conferences	03/04	PR
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03	PU
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03	PR
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	07/03	AQ
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	06/03	PU
Compugen: Q4 Earnings Snapshot	05/03	AQ
Compugen : Form 6-K- Fourth quarter and full year 2023 results	05/03	PU
Compugen Reports Fourth Quarter and Full Year 2023 Results	05/03	PR
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024	26/02	PR
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024	20/02	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Compugen Ltd. Deutsche Boerse AG

Actions

CW9

IL0010852080

Communiqués

Filtres